



Chicago Biomedical Consortium

presents

CBC Accelerator Network:

Overview of CBCAN and the CBC Accelerator Award program

**Thursday, July 20, 2017
4:00 - 7:00 PM**

Prentice Women's Hospital
Pavilion Conference Center
3rd Floor, Room L South
250 East Superior Street
Chicago, Illinois 60611



The CBC gratefully acknowledges support from the Searle Funds
at The Chicago Community Trust



CBC MISSION

The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. The CBC will:

- Stimulate research and education that bridge institutional boundaries,
- Enable collaborative and interdisciplinary research that is beyond the range of a single institution,
- Mentor and develop a strong cadre of biomedical leaders, researchers, and entrepreneurs in Chicago,
- Enhance and promote the development of the biomedical ecosystem in Chicago,
- Facilitate development of therapeutics that will, over the long term, improve the health of citizens of Chicago and beyond.

CBC LEADERSHIP

Lucy Godley, MD, PhD

CBC Scientific Director
The University of Chicago
Phone: 773 702-4140
Email: lgodley@medicine.bsd.uchicago.edu

Brian K. Kay, PhD

CBC Scientific Director
University of Illinois at Chicago
Phone: 312-355-0668
Email: bkay@uic.edu

Richard Morimoto, PhD

CBC Scientific Director
Northwestern University
Phone: 847-491-3340
Email: r-morimoto@northwestern.edu

Kathryn Stallcup, PhD

CBC Executive Director
Northwestern University
Phone: 847-467-0389
Email: k-stallcup@northwestern.edu

CBC STAFF

Karen Snapp, DDS, PhD

CBC Senior Associate Director
Northwestern University
Phone: 847-467-0633
Email: ksnapp@northwestern.edu

Kimberly Corn


CBC Associate Director,
Business Operations and Finance
Northwestern University
Phone: 847-467-0357
Email: k-corn@northwestern.edu

Jola Glotzer, MD

CBC Communications Director
The University of Chicago
Phone: 773-834-5132
Email: jolaglotzer@uchicago.edu

Corinna Kitcharoen, MBA

CBC Program Coordinator
University of Illinois at Chicago
Phone: 312-996-1311
Email: ckitch1@UIC.edu



Part I PROGRAM 3rd Floor, Room L South

- 4:15 PM** **INTRODUCTORY REMARKS**
 Overview of the meeting; introduction of Jim Audia
Katie Stallcup, CBC Executive Director
 Overview of CBCAN
Jim Audia, Incoming CBC Executive Director
- 4:30 PM** Overview of CBC's new Accelerator Award program
Lucy Godley, CBC Scientific Director, UChicago
- 4:40 PM** **PANEL DISCUSSION**
How can Accelerator Awards mesh with other funding mechanisms to facilitate commercialization and entrepreneurship?
 Moderated by: **Rick Morimoto**, CBC Scientific Director, NU
Scott Brun (AbbVie), Vice President of Scientific Affairs and Head, AbbVie Ventures
Nancy Harvey (UChicago), Managing Director, Polsky Center for Entrepreneurship and Innovation
Alicia Loffler (NU), Associate Provost for Innovation and New Ventures
Suseelan Pookote (UIC), Interim Director, Office of Technology Management
Nancy Sullivan (IllinoisVENTURES), CEO and Managing Director
- 5:10 PM** **PANEL DISCUSSION**
How does CBC engage and enlist other members of the ecosystem in selecting and mentoring Accelerator projects?
 Moderated by: **Brian Kay**, CBC Scientific Director, UIC
Steve Davidsen (AbbVie), Vice President, Oncology Discovery
Barbara Goodman (iBIO Institute), Senior Vice President, PROPEL
Steve Gould (Chicago Innovation Mentors at MATTER), Mentor-in-Residence
Jay McGill (Lilly), Senior Director, Science and Technology Partnerships, Lilly Research Labs
Thomas O'Halloran (NU), Professor of Chemistry; Director, Chemistry of Life Processes Institute
- 5:40 PM** **CLOSING REMARKS**
Jim Audia, Incoming CBC Executive Director

Part II NETWORKING 3rd Floor, Harris Family Atrium

- 5:50 PM** **NETWORKING RECEPTION**
7:00 PM **ADJOURN**

Jim Audia, PhD, the incoming CBC Executive Director




Jim Audia, currently Chief Scientific Officer of Constellation Pharmaceuticals in Cambridge, Massachusetts, will become Executive Director of the CBC effective August 1, 2017.

Jim has had a long and distinguished career in the pharmaceutical industry. After earning a PhD from the University of South Carolina and completing a postdoctoral fellowship at Yale University, Jim joined Eli Lilly in 1987 where he served in a variety of research and management positions for 24 years. He rose to the level of Executive Director of Lilly Research Laboratories and co-led Lilly's portfolio governance committee. In 2005 he was promoted to Distinguished Lilly Scholar, the highest rung of the scientific career ladder

at Lilly. Upon his retirement from Lilly in 2010, Jim was among the most prolific inventors in the company's history, with more than 90 issued patents at that time (now exceeding 100). In 2011 he joined Constellation Pharmaceuticals. Under Jim's leadership, Constellation translated its expertise in transcriptional control into a robust portfolio of candidate drugs to treat hematological malignancies and solid tumors. Jim will join Constellation's Board of Directors and will also serve as a scientific advisor. Additionally, Jim will remain as a member of the Chemistry Advisory Board of SAGE Therapeutics, and the Scientific Advisory Boards of the Tau Consortium of the Rainwater Charitable Foundation and Ribon Therapeutics.


Jim's wealth of experience in both large and small pharma is the ideal qualification to lead the CBC into Phase 2, with its increased emphasis on developing therapeutics and encouraging entrepreneurship. CBC Scientific Directors, Rick Morimoto (NU), Brian Kay (UIC) and Lucy Godley (UChicago), jointly and enthusiastically affirmed:

"We are delighted and excited to have Jim come on board as the new CBC Executive Director. Jim brings expertise and deep knowledge of drug discovery, as well as connections to an outstanding network of relationships with the pharma, biotech, and biotech investment communities. In addition to his scientific credentials, Jim has a deep commitment to strengthening and expanding the Chicago biomedical ecosystem. We have every confidence that Jim will continue his track record of success and will provide excellent leadership as the CBC pursues its ambitious goals for Phase 2."



Inspired by the SPARK program at Stanford, the **CBCAN program** is envisioned as a community, bringing together industry experts, university tech transfer officers, and researchers with discoveries that may have commercial potential. The aim is to move promising discoveries into and forward in the pipeline towards commercialization by providing the **early commercial guidance** that universities and university-based researchers need (see graphic below).

- CBCAN meetings will take place quarterly in a **central Chicago downtown location**,
- Meetings will feature presentations of **basic research that may have commercial potential**,
- Participants' feedback will be collected after each forum via **online survey** to continuously improve the CBCAN format,
- The CBCAN program will be central to and fully integrated with other CBC Phase 2 initiatives such as the new **CBC Accelerator Award program** and the new **CBC Entrepreneurial Fellows (EF) program** (see pages 6 and 7 for program descriptions).



CBC Phase 2 will expand its support of the commercialization pipeline. The pipeline from 'Discoveries to Patients' consists of several stages such as 'Translation to Business Application,' 'Company Formation' and 'Commercialization' (top). In turn, 'Translation to Business Application' entails a number of sub-stages, including 'Early Commercial Guidance,' 'Networking,' 'Tech Transfer,' 'Incubation' and 'Pre-Seed Funds'. During Phase 1, the CBC's biggest effort concentrated on 'Discoveries' (black arrow) although all sub-stages of 'Translation to Business Application' have also received CBC support (red arrows). By establishing CBCAN, CBC Phase 2 will strengthen that support by providing 'Early Commercial Guidance' and facilitating 'Networking' within the Chicago biomedical ecosystem (thick red arrows).



To align CBC's strengths with the Searle Consultants' strategy to "promote a new infrastructure for success for the Chicago biomedical industry," the CBC will introduce new initiatives in Phase 2 (2017-2021). Some of the programs that have been initiated in Phase 1 will continue to be offered during Phase 2 as well.

New Program

ACCELERATOR AWARD

The CBC will launch a new **Accelerator Award program** to support translational research and provide university researchers with "**early commercial guidance.**" Accelerator Awards will be used to support the initial, and therefore highest risk, stage of commercially-directed research. The program will encourage interactions between academic researchers and **industry/pharmaceutical experts** early in the development of projects and provide advice to award recipients in setting and progressing toward commercialization milestones. Award recipients will be mentored by faculty, industry experts, tech transfer officers and CBC personnel. Accelerator awardees will provide project updates at CBCAN meetings. The program will consist of two parts (A and B):

- **Part A:** Translational research projects will be evaluated by a team of reviewers that will include industry scientists. The application process will include an oral presentation at a CBCAN meeting. Full proposals must discuss commercial potential, including milestones and deliverables. Accelerator Part A awards will be for **\$100,000 for one year.**
- **Part B:** Only projects that have met proposed milestones during Part A awards will be invited to apply for **\$150,000 for one additional year.**
- **Applicants must be faculty with research programs at the CBC universities.**
- **Projects involving multi-institutional collaborative teams will be given strong preference,** although collaboration will not be required. **Collaborations could involve faculty scientists at any Chicago-area university,** but all institutions receiving CBC funding must agree to waive indirect cost recovery.

New Program

ENTREPRENEURIAL FELLOWS (EF)

A new **CBC Entrepreneurial Fellows (EF) program** will identify and support a cohort of postdoctoral fellows who are keen to work in the biotech start-up space of Chicago.

- Applications must be **jointly** submitted by a CBC university faculty member and a postdoctoral fellow candidate.
- Projects must be related to **biomedicine**, preferably pertaining to development of therapeutics or diagnostics.
- Projects must have clear translational milestones.
- The faculty mentor must agree that the fellow will have significant time available for **professional development** activities.
- Applications will be evaluated by the EF Review Board, composed of Tech Transfer Officers, industry experts, and faculty members who will consider both **potential commercial value** and **scientific merit**.
- Fellowship awards will be for **12 months**. If proposed milestones have been met and reasonable next steps are proposed, Fellows may apply for a **second year of funding**.
- EF Awards will be for **\$90,000** per year, to cover a salary of \$65,000 and benefits.

Continued Programs

CATALYST AWARD




The successful **CBC Catalyst Award program will be continued**, supporting the essential inputs into the commercialization pipeline by funding innovative collaborative research. **NEW STARTING FALL 2017: In addition to supporting basic biomedical research, projects with translational potential will be considered.**

- Awards will provide up to **\$250,000** for **up to two years**. Awards will be made based on scientific merit. Projects should address important areas of basic biological/biomedical or translational research that are risky, innovative and potentially transformative.
- **Applicants must be tenured or tenure-track faculty with research programs at the CBC universities who will initiate a new collaboration.**
- Research proposals must have Co-Principal Investigators from **at least two of the three CBC universities**.

EDUCATION AND OUTREACH

The CBC **will continue** to convene the local biomedical research community, including at the **annual CBC Symposium**, and provide the **CBC website** as an essential informational tool for the growing community.


Small MOLECULE DISCOVERY
ACADEMIA



Transformative
Biomedical
Research



Industry -
- Academia
Partnerships



CBCAN
Collaboration
Biotech



Entrepreneurial
Fellows



Education
Outreach

Catalyst
Award



Annual
Symposia



Accelerator
Award

